Kite Pharma Submits BLA to FDA for CAR T Cell Therapy, KTE-X19, for r/r Mantle Cell Lymphoma

Kite Pharma Submits BLA to FDA for CAR T Cell Therapy, KTE-X19, for rr Mantle Cell Lymphoma

Kite Pharma announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the investigational chimeric antigen receptor (CAR) T cell therapy, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). 

The BLA submission is based on data from the Phase 2 single-arm, multicenter, open-label ZUMA-2 trial. The trial enrolled 74 leukapheresed adult patients (≥18 years old) with MCL whose disease was refractory to or had relapsed following up to five prior lines of therapy, including anthracycline or bendamustine-containing chemotherapy, anti-CD20 monoclonal antibody therapy and the BTK inhibitors ibrutinib or acalabrutinib. Data demonstrated an overall response rate of 93 percent, including 67 percent with complete response, as assessed by an Independent Radiologic Review Committee (IRRC) following a single infusion of KTE-X19. In the safety analysis, Grade 3 or higher cytokine release syndrome (CRS) and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred. 

Kite plans to submit a Marketing Authorization Application for KTE-X19 in the European Union in early 2020. 

KTE-X19 has been granted Breakthrough Therapy Designation (BTD) by the FDA and Priority Medicines (PRIME) by the European Medicines Agency (EMA) for relapsed or refractory MCL.

About KTE-X19

KTE-X19 is an autologous, anti-CD19 CAR T cell therapy. KTE-X19 uses the XLP™ manufacturing process that includes T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is a necessary step in certain B-cell malignancies with evidence of circulating lymphoblasts.

About Mantle Cell Lymphoma

MCL is a rare form of non-Hodgkin lymphoma (NHL) that arises from cells originating in the “mantle zone” of the lymph node and typically affects men over the age of 60.